evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

55 questions · 55 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 13 · 23.6%GRADE not reported 0 · 0%Very low 13 · 23.6%Low 20 · 36.4%Moderate 6 · 10.9%High 3 · 5.5%

beta‐lactam monotherapy vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

All cause mortality · people with cancer who have febrile neutropenia

beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).

1 finding from 1 review

beta‐lactam monotherapy vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia

beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).

1 finding from 1 review

beta‐lactam monotherapy vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia

beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).

1 finding from 1 review

beta‐lactam monotherapy vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Treatment failure ‐ different beta‐lactam · people with cancer who have febrile neutropenia

beta‐lactam monotherapy may leads to lower treatment failure ‐ different beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review